REG - Cellbxhealth PLC - Further Update on Funding
05/11/2025 18:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251105:nRSE3856Ga&default-theme=true
RNS Number : 3856G Cellbxhealth PLC 05 November 2025
NOT FOR DISTRIBUTION INTO THE UNITED STATES
The information contained in this announcement does not constitute an offer to
sell, or a solicitation of an offer to buy, securities in the United States.
The securities referred to herein have not been and will not be registered
under the US Securities Act of 1933, as amended (the "Securities Act"), or
with any securities regulatory authority of any state or other jurisdiction of
the United States, and may not be offered, sold, resold, transferred,
delivered or distributed, directly or indirectly, in any form, in or into, the
United States, except pursuant to an applicable exemption from, or in a
transaction not subject to, the registration requirements under the Securities
Act and in compliance with any applicable securities laws of any state or
other jurisdiction of the United States. No public offering or sale of
securities in the United States will be made.
CELLBXHEALTH plc ("the Company")
Further Update on Funding
CELLBXHEALTH plc (AIM:CLBX), a global leader in circulating tumour cell (CTC)
intelligence, announces, further to the interim results of 9 October 2025, the
Company currently has a cash runway into early 2026. CelLBxHealth has
recently commenced discussions with a number of shareholders and is seeking to
raise approximately £6m with the intention to make an offer to retail
investors alongside an institutional placing.
The Company expects to announce the fundraise by early December and will make
further updates as appropriate.
For further information:
CelLBxHealth plc +44 (0) 1483 343434
Peter Collins, Chief Executive Officer investor@CelLBxHealth.com
Cavendish (NOMAD and Broker)
Geoff Nash / Isaac Hooper (Corporate Finance) +44 (0) 20 7220 0500
Sunila de Silva (Corporate Broking)
Nigel Birks (Life Science Specialist Sales)
FTI Consulting
Simon Conway, Ciara Martin, Sam Purewal +44 (0) 203 727 1000
The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a
regulatory information service, this information is considered to be in the
public domain.
Notes for editors
About CelLBxHealth plc
CelLBxHealth plc is a global precision CTC intelligence company specialising
in innovative circulating tumour cell (CTC) solutions for use in research,
drug development and clinical oncology. Its patent-protected Parsortix®
platform harvests CTCs from blood and can be seamlessly integrated with
existing laboratory instruments for comprehensive downstream analysis -
including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial activities centre on (1) Product Sales: Accelerating Parsortix
platform adoption and consumable sales through CROs* and clinical lab
partnerships. (2) Lab Developed Tests (LDTs): Strategic partnerships combined
with a focused in-house development programme (3) Laboratory services:
Clinical trial support and assay development.
The product portfolio comprises the Parsortix® platform with associated
consumables and assays. Laboratory services are delivered from CelLBxHealth's
GCLP certified UK laboratory, providing bespoke clinical-trial support and
assay development.
For more information, visit https://cellbxhealth.com/.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END FURUVRWRVWUARAA
Copyright 2019 Regulatory News Service, all rights reserved